- Home
- OSUR vs PCYO Comparison
OSUR vs PCYO Comparison
Compare OSUR & PCYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- PCYO
- Stock Information
- Founded
- OSUR 2000
- PCYO 1976
- Country
- OSUR United States
- PCYO United States
- Employees
- OSUR N/A
- PCYO N/A
- Industry
- OSUR Medical/Dental Instruments
- PCYO Water Supply
- Sector
- OSUR Health Care
- PCYO Utilities
- Exchange
- OSUR Nasdaq
- PCYO Nasdaq
- Market Cap
- OSUR 223.0M
- PCYO N/A
- IPO Year
- OSUR 1986
- PCYO N/A
- Fundamental
- Price
- OSUR $2.60
- PCYO $10.44
- Analyst Decision
- OSUR Hold
- PCYO
- Analyst Count
- OSUR 2
- PCYO 0
- Target Price
- OSUR $5.50
- PCYO N/A
- AVG Volume (30 Days)
- OSUR 444.5K
- PCYO 96.4K
- Earning Date
- OSUR 05-07-2025
- PCYO 04-09-2025
- Dividend Yield
- OSUR N/A
- PCYO N/A
- EPS Growth
- OSUR N/A
- PCYO 118.08
- EPS
- OSUR N/A
- PCYO 0.59
- Revenue
- OSUR $161,626,000.00
- PCYO $29,911,000.00
- Revenue This Year
- OSUR N/A
- PCYO N/A
- Revenue Next Year
- OSUR $7.55
- PCYO N/A
- P/E Ratio
- OSUR N/A
- PCYO $17.63
- Revenue Growth
- OSUR N/A
- PCYO 58.85
- 52 Week Low
- OSUR $2.69
- PCYO $8.94
- 52 Week High
- OSUR $5.59
- PCYO $14.63
- Technical
- Relative Strength Index (RSI)
- OSUR 30.12
- PCYO 52.88
- Support Level
- OSUR $2.91
- PCYO $9.83
- Resistance Level
- OSUR $3.09
- PCYO $10.77
- Average True Range (ATR)
- OSUR 0.11
- PCYO 0.32
- MACD
- OSUR -0.02
- PCYO 0.08
- Stochastic Oscillator
- OSUR 26.47
- PCYO 65.08
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.